L. Joe Dunaway, MD, MS
Potential Financial Conflicts of Interest: None disclosed.
Dunaway L.; β-Blockers and Progression of Coronary Atherosclerosis. Ann Intern Med. 2008;148:404. doi: 10.7326/0003-4819-148-5-200803040-00016
Download citation file:
Published: Ann Intern Med. 2008;148(5):404.
TO THE EDITOR:
In their recent meta-analysis, Sipahi and colleagues (1) propose a mechanism of decreased atherosclerosis progression attributed to β-blockers. Why do we not see this when β-blockers are used in the treatment of hypertension? Prospective studies have shown no decreased incidence of myocardial infarction (MI) and stroke in patients treated with β-blockers versus placebo. How can this mechanism of decreased atherosclerosis progression be active in a patient who has had MI treated with β-blockers and not in a patient with hypertension treated with β-blockers? I think this contradiction demonstrates a fatal flaw in the conclusion reached by the meta-analysis.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only